RxDoctor Payments Data

Mark McCune, MD

Dermatology · Overland Park, KSNPI 1871607267

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,842 of the $4,768 with a category attached, or 80.6%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,668 and has fallen 99.1% since, to $15 in 2025.

$4,768in general payments, 2019–2025

Across 190 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$1K
  • AbbVie$825
  • Organogenesis Inc.$402
  • LEO Pharma Inc.$395
  • Novartis$352
  • Pfizer$290
  • plus $1K from 20 others
$1,973,365in research payments, 2019–2025

Across 627 payments — averaging $3147.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$553K
  • Eli Lilly$268K
  • AbbVie$234K
  • Pfizer$178K
  • Incyte Corporation$159K
  • Amgen$123K
  • plus $459K from 15 others

What the payments were for

  • Travel & lodging$85018%
  • Food & beverage$3,84281%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,768 in reported general payments places this provider in the 75th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$150,635
Medicare patients
189
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin162$435
Doxycycline Monohydrate38$259
Prednisone11$18

Paid to pharmacies, not to this prescriber.

Other dermatology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →